TEL AVIV, Israel, Feb. 2, 2015 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that it will report its financial results for the fourth quarter and fiscal year ended December 31, 2014 before the market open, and will host a corporate update conference call and webcast on Thursday, February 12 at 8:30am Eastern Time.
Conference Call & Webcast | |
Thursday, February 12 @ 8:30am Eastern Time/5:30am Pacific Time | |
Domestic: | 855-469-0611 |
International: | 484-756-4341 |
Passcode: | 74833931 |
Webcast: | http://www.alcobra-pharma.com/indexInvestor.cfm |
Replays available through February 26, 2015 | |
Domestic: | 855-859-2056 |
International: | 404-537-3406 |
Passcode: | 74833931 |
About Alcobra Ltd.
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. MDX has completed multiple Phase II studies and a Phase III study in adults with ADHD. The company is conducting separate Phase II trials in pediatric ADHD and Fragile X Syndrome. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.